secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001193125-26-038539
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027
--------------------------------------------------------------------------------

- Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.
- Investors include Balyasny, Caligan, Commodore, Deep Track, Nantahala, Pivotal, Spruce Street, TCGX, Trails Edge.
- Net proceeds to fund Phase 2 trial of LB-102 as adjunctive MDD treatment and for working capital.
- Phase 2 trial: 380 patients, 50 sites U.S./Europe, randomized 1:1 vs placebo, primary endpoint MADRS-10 at week 6.
- Trial to start early 2027; topline results expected first half 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/0001193125-26-038539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/d943290d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-038539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer